Stock Scorer

Royalty Pharma plc (RPRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 250M 500M 750M Q3 '21: 585.8M Q4 '21: 575.7M Q1 '22: 562M Q2 '22: 536M Q3 '22: 573.5M Q4 '22: 565.7M Q1 '23: 684M Q2 '23: 538.2M Q3 '23: 536.3M Q4 '23: 596.1M Q1 '24: 568M Q2 '24: 537.3M Q3 '24: 564.7M Q4 '24: 593.6M Q1 '25: 568.2M Q2 '25: 578.7M Q3 '25: 609.3M Q4 '25: 622M Q1 '26: 630.6M Q2 '26: 674.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-300M 0 300M 600M 900M Q2 '21: 744.9M Q3 '21: 303.1M Q4 '21: 153.4M Q1 '22: 219.7M Q2 '22: 377.8M Q3 '22: 192.2M Q1 '23: 479M Q2 '23: 248.8M Q3 '23: 151.4M Q4 '23: 612.9M Q1 '24: -73.8M Q2 '24: 269.6M Q3 '24: 735.1M Q4 '24: 361.5M Q1 '25: 534.2M Q2 '25: 209.8M Q3 '25: 427.2M Q4 '25: 388.4M Q1 '26: 563M Q2 '26: 133.1M Q3 '21 Q2 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

0 200M 400M 600M Q2 '21: 440.8M Q3 '21: 101.9M Q4 '21: 7.9M Q1 '22: 51.8M Q2 '22: 304.5M Q3 '22: 142.7M Q1 '23: 340.8M Q2 '23: 227.6M Q3 '23: 72.1M Q4 '23: 494.3M Q1 '24: 4.8M Q2 '24: 102M Q3 '24: 544M Q4 '24: 208.2M Q1 '25: 239.3M Q2 '25: 32.2M Q3 '25: 288.2M Q4 '25: 214.2M Q1 '26: 294.7M Q2 '26: 17.9M Q3 '21 Q2 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

0 400M 800M 1.2B Q3 '21: 469.8M Q4 '21: 490M Q1 '22: 460.3M Q2 '22: 575M Q3 '22: 538.8M Q4 '22: 569.9M Q1 '23: 1B Q2 '23: 607.8M Q3 '23: 573.5M Q4 '23: 772.6M Q1 '24: 664.6M Q2 '24: 658.2M Q3 '24: 703.6M Q4 '24: 742.5M Q1 '25: 596.1M Q2 '25: 364M Q3 '25: 702.6M Q4 '25: 827.1M Q1 '26: 718.2M Q2 '26: 728.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Shares Outstanding Quarterly

0 250M 500M 750M Q2 '20: 354M Q3 '20: 370M Q1 '21: 607.1M Q2 '21: 607.2M Q3 '21: 607.2M Q1 '22: 607.2M Q2 '22: 607.2M Q3 '22: 607.2M Q1 '23: 607.3M Q2 '23: 605.9M Q3 '23: 601.1M Q1 '24: 597.5M Q2 '24: 596.9M Q3 '24: 592.7M Q1 '25: 578.1M Q2 '25: 562.3M Q3 '25: 559.6M Q1 '26: 556.8M Q2 '26: 556.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 0.90 1.80 2.70 Q2 '21: 2.49 Q3 '21: 1.94 Q4 '21: 1.50 Q1 '22: 1.44 Q2 '22: 1.06 Q3 '22: 1.14 Q4 '23: 2.52 Q1 '24: 1.77 Q2 '24: 1.50 Q3 '24: 2.55 Q4 '24: 1.92 Q1 '25: 2.46 Q2 '25: 2.30 Q3 '25: 1.76 Q4 '25: 1.79 Q1 '26: 1.91 Q2 '26: 1.88 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for RPRX: Gross Profit, Cost of Revenue, Free Cash Flow. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.